Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | HEXA | P06865 | 1/20 | 0.56 |
| ▸ | HEXB | P07686 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572660 | 0.90 | FTO (0.64) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL21175626 | 0.87 | FTO (0.56) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL5318570 | 0.86 | FTO (0.66) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL19732385 | 0.86 | FTO (0.55) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL17576188 | 0.85 | FTO (0.61) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL11440392 | 0.84 | FTO (0.71) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL5457321 | 0.84 | FTO (0.66) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL3299639 | 0.84 | FTO (0.51) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL14507167 | 0.84 | FTO (0.61) | FTOCYP2D6HEXAHEXBCYP1A2 | |
| SCHEMBL4188839 | 0.83 | FTO (0.70) | FTOCYP2D6HEXAHEXBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | claimed |
| EP-1742920-A2 | NAPHTHALIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Unibioscreen S.A. (BE) | 2007-01-17 | — | — | EP | claimed |
| WO-2005105753-A2 | NAPHTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2005-11-10 | — | — | WO | claimed |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | NPM1, NAPRT, NUTF2 | FTO 3049/4885CYP2D6 62/4885HEXA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.